This trial is researching a new brain-training smartphone app that aims to reduce people’s automatic responses to images of alcohol to see if it can help people reduce their alcohol craving and consumption.

The trial will be recruiting soon and will compare different versions of the app to test whether the brain training can help people who are experiencing alcohol problems and want to reduce or stop drinking, but who are not seeking treatment.

MDMA may be a promising approach to improve response to therapy for this population. Emerging evidence suggests that MDMA-assisted therapy may be of promise for PTSD, and has demonstrated a good safety profile and potential efficacy in alcohol dependence.

This trial will evaluate the clinical efficacy and tolerability of MDMA-assisted COPE relative to a control-assisted COPE.

N-acetylcysteine (NAC) may be helpful to reduce drinking and craving in individuals with alcohol use disorder.

This multi-site trial will examine the benefits of NAC on participants' alcohol use, as well as other measures of change in well-being, mood and sleep. It is anticipated that the findings will contribute to evidence for the future use of NAC in the treatment of alcohol use disorder.

These trials are examining a new brain-training app that delivers alcohol avoidance training in two different settings.
1. One trial aims to test whether the app can help people in outpatient treatment reduce their alcohol use.
2. The second trial aims to test whether the app can help prevent alcohol relapse among people leaving residential rehabilitation.